{"entity":{"id":"nct05518045","kind":"trial","name":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of LM-108 and Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, active and no longer recruiting.","summary":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05518045 by LaNova Medicines Limited, with 392 participants enrolled, started 2022-08-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: LM-108 and Toripalimab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05518045","url":"https://clinicaltrials.gov/study/NCT05518045"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lm-108","toripalimab"],"companies":["lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05518045","phase":"1/2","setting":"An Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108 for Injection as Monotherapy or in Combination With Antitumor Therapies in Patients With Advanced Solid Tumors","sponsor":"LaNova Medicines Limited","enrolled":392,"outcomes":[]},"route":"/trials/nct05518045/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"}]}}